Profile data is unavailable for this security.
About the company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
- Revenue in USD (TTM)388.52m
- Net income in USD127.34m
- Incorporated1996
- Employees127.00
- LocationInnoviva Inc1350 OLD BAYSHORE HIGHWAY, SUITE 400BURLINGAME 94010United StatesUSA
- Phone+1 (650) 238-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.inva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 723.31m | 111.63m | 1.31bn | 2.03k | 12.64 | 1.70 | 7.82 | 1.81 | 2.26 | 2.26 | 14.69 | 16.76 | 0.4505 | 2.32 | 5.05 | 356,659.30 | 6.95 | 9.84 | 7.84 | 11.71 | 49.36 | 49.55 | 15.43 | 17.15 | 2.21 | 8.96 | 0.4397 | 0.00 | 13.59 | 17.82 | 15.98 | 26.66 | -0.2486 | -- |
| Collegium Pharmaceutical Inc | 757.07m | 58.44m | 1.45bn | 357.00 | 28.56 | 5.27 | 5.09 | 1.91 | 1.60 | 1.60 | 19.94 | 8.70 | 0.467 | 8.51 | 3.27 | 2,120,636.00 | 3.60 | 4.11 | 5.02 | 6.64 | 57.22 | 55.50 | 7.72 | 8.48 | 1.27 | 2.23 | 0.7462 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.62bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 379.59m | -29.23m | 1.63bn | 493.00 | -- | -- | -- | 4.30 | -0.5866 | -0.5866 | 7.49 | -- | 0.3471 | 0.5336 | 5.44 | 769,959.40 | -2.67 | -17.90 | -3.34 | -23.26 | 99.29 | -- | -7.70 | -53.74 | 5.97 | -- | 0.4975 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Innoviva Inc | 388.52m | 127.34m | 1.70bn | 127.00 | 17.59 | 1.68 | 10.14 | 4.37 | 1.29 | 1.29 | 4.57 | 13.51 | 0.292 | 1.98 | 4.21 | 3,059,221.00 | 9.57 | 20.06 | 10.66 | 22.10 | 81.50 | -- | 32.78 | 62.81 | 13.33 | 18.15 | 0.2031 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.74bn | 897.00 | 47.44 | 3.44 | 13.33 | 2.10 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.74bn | 143.00 | -- | 41.66 | -- | 276.49 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.77bn | 382.00 | -- | 37.57 | 129.10 | 7.06 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Vericel Corp | 258.72m | 13.08m | 1.82bn | 357.00 | 192.09 | 5.65 | 78.45 | 7.03 | 0.1872 | 0.1872 | 4.86 | 6.37 | 0.6133 | 4.00 | 4.75 | 724,697.50 | 3.10 | -1.03 | 3.46 | -1.18 | 73.81 | 69.10 | 5.06 | -1.61 | 4.47 | -- | 0.002 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.86bn | 1.37k | -- | 1.41 | -- | 0.7723 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Aurinia Pharmaceuticals Inc | 265.81m | 77.84m | 1.88bn | 300.00 | 25.37 | 5.13 | 19.28 | 7.06 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Organon & Co | 6.30bn | 501.00m | 1.92bn | 10.00k | 3.84 | 2.12 | 2.28 | 0.3049 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.93bn | 325.00 | -- | 2.93 | -- | 37.21 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Ultragenyx Pharmaceutical Inc | 672.72m | -575.44m | 1.98bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 2.00bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.07bn | 246.00 | 11.34 | 2.48 | 9.90 | 2.51 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
Data as of Feb 17 2026. Currency figures normalised to Innoviva Inc's reporting currency: US Dollar USD
52.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 9.46m | 12.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.34m | 9.82% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 4.21m | 5.63% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 4.18m | 5.60% |
| Sarissa Capital Management LPas of 30 Sep 2025 | 2.82m | 3.77% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.80m | 3.74% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 2.36m | 3.15% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 2.24m | 3.00% |
| Systematic Financial Management LPas of 31 Dec 2025 | 2.11m | 2.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.75m | 2.34% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
